Corning Jereh Pharmaceutical-B (09966.HK): The new drug application for Anrituzumab (KN026) for the neoadjuvant treatment of HER2-positive breast cancer has been accepted by the National Medical Products Administration.

Zhitong Finance APP news, Corning Pharmaceutical-B (09966.HK) announced that its New Drug Application (NDA) for the combination of Anituzumab (trade name: Enituz; research code: KN026) and injectable albumin-bound Docetaxel (HB1801), developed in collaboration with Shanghai Jinmant Biotech Co., Ltd., a subsidiary of SSY Group (01093.HK), for the neoadjuvant treatment of HER2-positive (HER2+) early-stage or locally advanced breast cancer has been accepted by the National Medical Products Administration of China and is included in the priority review and approval process.